Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia

25 May 2022

Abstract excerpt

BACKGROUND: The presence of TP53 mutations is associated with an unfavorable outcome in patients allografted for acute myeloid leukemia (AML), leading some to question the benefit of an allogeneic stem cell transplantation (allo-SCT) for this patient group, although this has not been studied in a large cohort. METHODS: A total of 780 patients with AML in first complete remission, with either intermediate- or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35612815
DOI: 10.1002/cncr.34268

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemiaPMID 35612815Read ↗

Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype.Semantic proximity Read ↗

TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantationSemantic proximity Read ↗

TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.Semantic proximity Read ↗

The prognostic impact of myeloid co-mutation burden in TP53-mutated AML/MDS after allogeneic stem cell transplantation: a multicenter retrospective analysis.Semantic proximity Read ↗

Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutationsSemantic proximity Read ↗

Transplant for TP53-mutated MDS and AML: because we can or because we should?Semantic proximity Read ↗

Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutationsSemantic proximity Read ↗

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.Semantic proximity Read ↗

Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience.Semantic proximity Read ↗

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.Semantic proximity Read ↗

Clinical and Molecular Characterization of p53-Mutated Acute Myeloid LeukemiaSemantic proximity Read ↗

Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.